Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenqi Changtai Mixture (参歧肠泰合剂) is a traditional Chinese medicine (TCM) oral liquid developed and manufactured by Chongqing Sainuo Biological Pharmaceutical. It is primarily indicated for the treatment of gastrointestinal disorders associated with Spleen deficiency, including chronic diarrhea, functional gastrointestinal dysfunction, and intestinal flora imbalance. The formulation typically utilizes herbal extracts such as Codonopsis (Dangshen) and Astragalus (Huangqi) to tonify Qi and strengthen the spleen. According to the developer's pipeline, it is also characterized as a probiotic-related combination therapy, designed to regulate the intestinal microenvironment, restore microbial balance, and improve gastrointestinal mucosal health. It is currently approved and marketed in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shenqi changtai mixture.